Introduction
Sclerotic graft-versus-host disease (GVHD) represents a distinctive phenotype of chronic GVHD, characterized by fibrosis of skin or fascia, and is often associated with severe disability and morbidity after allogeneic hematopoietic cell transplantation. 1 The 3-year cumulative incidence of sclerosis is 20% after initial systemic treatment among patients with chronic GVHD, and the prevalence reaches 53% in patients with severe chronic GVHD. 2, 3 Pathogenic mechanisms of sclerotic GVHD remain elusive, but the cutaneous clinical manifestations resemble systemic sclerosis, a rare autoimmune disease whose risk is influenced by genetic polymorphisms. Both diseases are characterized by thickening of the skin due to accumulation of collagen and extensive fibrosis, but some manifestations differ. For example, systemic sclerosis often causes pulmonary hypertension, renal dysfunction and cardiac dysfunction, whereas these manifestations rarely occur in patients with sclerotic GVHD. 4, 5 Therefore, pathogenic mechanisms of the two diseases are thought to differ, although they might share some similar mechanisms. 4, 6 To date, genetic risk factors for sclerotic GVHD have not been well defined, but candidate gene and genome-wide association studies (GWAS) have identified single-nucleotide polymorphisms (SNPs) associated with systemic sclerosis. 7 These SNPs include human leukocyte antigen (HLA) and non-HLA variants involved in adaptive and innate immune responses. We hypothesized that the same SNPs might also have associations with development of sclerosis in patients with chronic GVHD if the two diseases have similar pathogenic mechanisms. Therefore, we selected candidate SNPs that have well-documented association with systemic sclerosis and examined their association with risk of sclerosis in patients with chronic GVHD. Identification of such associations would suggest similar pathogenic mechanisms between the two diseases and might help to elucidate genetic mechanisms and treatment targets. Chronic GVHD was diagnosed by NIH consensus criteria. 1 The onset of sclerotic GVHD was defined when manifestations of cutaneous sclerosis, fasciitis or joint contracture were first documented in the medical record.
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Sample preparation, genotyping and imputation
All recipient and donor samples were collected before transplantation according to approved research protocols. Genomic DNA was extracted from blood mononuclear cells or EBV transformed B-lymphocyte cell lines using a Puregene kit (Qiagen, Valencia, CA imputed locus, given all of the observed genotypes in the flanking region. The imputed SNP genotype was retained only if the average posterior probability exceeded 0.8. The imputed genotype was treated as missing if the average posterior probability was less than 0.8. The call rate reflects the percentage of non-missing genotypes in each platform, and SNPs were treated as a quality control "failure" and excluded from analyses if the call rate in any typing platform was less than 0.90.
HLA-DPA1 and -DPB1 genotypes were determined by next generation sequencing (MiSeq, Illumina System, San Diego) using commercial NGS HLA reagents (Scisco Genetics Inc.
Seattle) in 165 recipients and 172 donors and were imputed in 613 recipients and 636 donors with the use of SNP genotypes according to methods described previously. 8 The frequencies of HLA-DPA1 and -DPB1 alleles in the study cohort were comparable to those reported in a large population based study.
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Statistical analysis
Sclerotic manifestations present at the onset of initial treatment for chronic GVHD were treated as an event at day 1 after treatment, and all patients were included in the analysis. 3 In this cohort study, Cox regression models were used to examine allelic (additive) and genotypic (dominant and recessive) associations of donor and recipient SNPs with the risk of sclerotic GVHD. 10 Results were analyzed without and with adjustments for clinical risk factors as defined in our previous study. 3 These included stem cell graft source, HLA matching at A, B, C, DRB1
and DQB1 loci, donor-recipient ABO compatibility, and total body irradiation exposure. 3 
Results
Characteristics of the study cohort
The median age of the patients was 48 years (range, 1 to 78). Five hundred two (59%) patients were males, 694 (82%) were Caucasian, and 745 (88%) received mobilized blood cell grafts.
The median follow-up after onset of chronic GVHD among survivors was 81 months (range, 6 to 135). The cumulative incidence of sclerotic manifestations was 24% (95% confidence interval
[CI], 21% to 27%) at 5 years after the initial systemic treatment of chronic GVHD. Other demographics of the study cohort are summarized in Table 1 .
Candidate genes and SNPs
A broad search of the PubMed database identified 15 SNPs in 13 genes that were associated with susceptibility to systemic sclerosis and met all of the required criteria described in the Table 2 ). The MAF for each SNP was consistent with the values reported in studies of systemic sclerosis. [11] [12] [13] [14] [15] [16] [17] [18] [19] Two SNPs (rs11642873 and rs1234314) did not pass quality control because of low call rates on one of the genotyping platforms (Supplemental Table S1 ). Supplemental Table S2 shows the genotype distributions and minor allele frequencies for each SNP, according to the presence or absence of sclerosis.
Candidate SNPs associated with risk of sclerotic GVHD
Three SNPs showed statistically significant associations with risk of sclerosis in patients with chronic GVHD ( (HLA-DPA1) were inconclusive as to whether the donor and recipient associations are independent. Cumulative incidence frequencies of sclerotic GVHD according to genotypes of these three SNPs are shown in Figure 1 . Results for other candidates are shown in Supplemental Table S3 . Overall, adjustment had only minor effects on the association results.
Polymorphisms in the HLA-DRA and HLA-DQB1 were not statistically associated with risk of sclerotic GVHD, although power to observe a statistically significant association is ≥ 80% based on the odds ratios reported for systemic sclerosis shown in Table 2 .
Analysis of HLA-DPB1 mismatching
Results for rs987870 (HLA-DPA1) motivated further exploration of the association between HLA-DPB1 mismatching and the risk of sclerotic GVHD. Among 619 HLA-A, B, C, DRB1 and DQB1-matched patient and donor pairs, recipient mismatching at HLA-DPB1 was present in 243 (39%) pairs but was not statistically associated with the risk of sclerotic GVHD (hazard ratio 1.05; 95% CI, 0.76 to 1.45; P=0.77). Likewise, non-permissive recipient T-cell epitope mismatching at HLA-DPB1 20 was present in 56 (9%) pairs but was not statistically associated with the risk of sclerotic GVHD (hazard ratio 0.58; 95% CI, 0.30 to 1.14; P=0.11). The recently reported SNP rs92777534 linked to HLA-DP expression 21 was also not statistically associated with the risk of sclerotic GVHD (data not shown).
Analysis of HLA-DPA1~B1 haplotype and HLA-DP P1 peptide-binding pocket
The risk of sclerotic GVHD was increased when donors or recipients were homozygous for the rs987870 minor C allele but was paradoxically decreased when donors or recipients were heterozygous, as compared to donors or recipients homozygous for the major T allele ( Figure 1 ).
We used two approaches to unravel this paradox. Since this SNP is located in the 5'-flanking region of the HLA-DPA1 locus, we tested whether any of the most frequent HLA-DPA1~DPB1
haplotypes were associated with the risk of sclerotic GVHD (Table 4) 
. 9 As a second approach in unraveling the paradox, we evaluated associations of each P1 pocket motif with the risk of sclerotic GVHD (Table 5) . Previous studies have shown significant negative linkage disequilibrium between HLA-DPA1 alleles encoding Q and HLA-DPB1 alleles encoding GPM. Haplotype frequencies for these Q and GPM encoding alleles occur much less frequently than expected from their respective individual frequencies. Figure S1 ). Therefore, we defined P1 pocket motifs by considering DPα~DPβ heterodimers encoded in trans together with those encoded in cis. The risk of sclerotic GVHD was decreased in recipients who had HLA-DPA1 and HLA-DPB1 alleles encoding Q~GPM P1 pockets compared with those who did not (adjusted hazard ratio 0.62; 95% CI, 0.42 to 0.92; P=0.02) ( Table 5 and Figure 2B ).
With adjustments for the presence of DPA1*01:03~DPB1*04:01 haplotypes and Q~GPM P1 pockets, differences in the risk of sclerotic GVHD between rs987870 heterozygotes and TT homozygotes were not statistically significant (Supplemental Tables S4 and S5 ). Within the entire cohort, rs987870 genotypes, DPA1*01:03~DPB1*04:01 haplotypes and Q~GPM P1
pockets showed independent associations with the risk of sclerotic GVHD (Table 6 ).
Discussion
We examined 13 candidate SNPs that had well-documented association with susceptibility to systemic sclerosis, under the hypothesis that the same SNPs may also have associations with development of sclerotic GVHD if the two diseases share similar pathogenic mechanisms. The candidate SNPs all map to genes or regions involved in immune function. We found that donor rs10516487 (BANK1), and donor and recipient rs2056626 (CD247) and rs987870 (5'-flanking region of HLA-DPA1) were associated with the risk of sclerosis in patients with chronic GVHD.
Despite adequate power to detect associations, candidate SNPs in HLA-DRA and HLA-DQB1
did not show statistically significant associations with risk of sclerotic GVHD. These results highlight similarities and differences in the mechanisms that cause sclerotic GVHD as compared with systemic sclerosis and suggest a critical role of the adaptive immune system including Bcell activation, T-cell antigen receptor response, and HLA-DP-mediated antigen presentation in the pathogenic mechanisms of both sclerotic GVHD and systemic sclerosis.
BANK1 is expressed exclusively in B cells and encodes a signaling molecule with stimulatory and inhibitory functions. BANK1 is a Lyn tyrosine kinase substrate that promotes As compared with the rs10516487 C major allele, the T minor allele decreases BANK1 expression, reduces BANK1 variants with increased potential for self-association and thereby reduces B cell responses. 26 In several large studies, the same minor allele has been associated with decreased susceptibility to systemic sclerosis, 11, 27 systemic lupus erythematosus 24 and rheumatoid arthritis. 25 These results suggest that sclerotic GVHD shares a BANK1-mediated pathogenic mechanism with several autoimmune diseases.
These results also suggest that sclerotic GVHD might be ameliorated or prevented by inhibition has shown allelic associations with reduced susceptibility to systemic sclerosis in four independent studies. 13, 14, 19, 35 In addition, minor alleles of two other CD247 SNPs in linkage disequilibrium with rs2056626 were associated with reduced susceptibility to rheumatoid arthritis, celiac disease and juvenile idiopathic arthritis. [36] [37] [38] While causal effects of these SNPs on CD247
expression and function have not been completely characterized, variation in this gene correlated with altered T-cell activation and autoimmune diabetes in mice. 39 In our study, the rs2056626 G minor allele in both recipients and donors showed allelic and dominant associations with increased risk of sclerosis in patients with chronic GVHD. These results suggest that variable expression of CD3ζ might play a pathogenic role in sclerotic GVHD and other autoimmune diseases by altering T-cell receptor signaling. We note that the rs2056626 (CD247) minor allele was associated with an increased risk of sclerotic chronic GVHD but with a decreased susceptibility to systemic sclerosis. We can only speculate that the downstream effect of variable signaling through the TCR may differ in the context of an alloimmune response as compared to the autoimmune response involved in systemic sclerosis.
HLA-DP variants have been associated with susceptibility to certain immune-mediated diseases. 14, 40 We found that SNP rs987870 (HLA-DPA1) was associated with the risk of sclerotic GVHD. The same SNP has been associated with increased susceptibility to asthma as well as systemic sclerosis. In previous studies, HLA-DPB1 mismatching between the donor and recipient was associated with an increased risk of acute GVHD. 42 In the present study, neither HLA-DPB1 mismatching nor HLA-DPB1 non-permissive mismatching was statistically associated with risk of sclerotic GVHD. The recently reported SNP rs92777534 linked to HLA-DP expression 21 was also not statistically associated with the risk of sclerotic GVHD. Taken together, these results
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This study has limitations. Power to examine some of the weaker SNP associations reported for systemic sclerosis was low, and our analysis did not adjust for multiple comparisons. We were unable to determine whether the donor and recipient CD247 and HLA-DPB1 genotypes contribute independently to the risk of sclerosis. No other cohort currently has sufficient numbers of patients with chronic GVHD, together with the annotated onset of sclerosis and the DNA samples needed for a replication study. Therefore, collaborative efforts will be needed so that future studies could verify whether positive results from this study hold true in other cohorts of patients with chronic GVHD.
Our findings suggest that genetic variation can modify the immune pathology and significantly alter the disease phenotype of chronic GVHD. Our results also support the hypothesis that HLA-DP-mediated presentation of specific peptides may have pathogenic or protective effects related to sclerotic GVHD. Further efforts to identify such peptides and genetic variations associated with specific phenotypes of chronic GVHD may expand our understanding of the responsible pathogenic mechanisms, thereby suggesting novel approaches for targeted therapy. 
